Advancing human health and creating healthier lives
At Charles River, we provide products and services to support the discovery, non-clinical development, and safe manufacture of novel drugs and therapeutics. As the only contract research organization (CRO) with an integrated portfolio that spans the drug research process from target discovery through non-clinical development and manufacturing solutions, we partner with our clients to deliver innovative, safe, and effective therapies, as quickly and efficiently as possible.
Charles River is committed to providing the scientific expertise our clients require when and where they need it. We have built upon our original core competency of research model technologies to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, and a suite of products and services to support our clients’ manufacturing activities. Our products and services are provided through three business segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing. With approximately 19,000 employees located in over 100 facilities across 20 countries, we are passionate about our role in improving the quality of people’s lives and we are proud to have worked on more than 80% of the FDA drug approvals in each of the last three years. The work that we do is essential to help our clients discover and develop new drugs for the patients who need them.
May 27, 2021 8:30 AM - 11:30 AM ET
15%
16%
5-year Compound Annual Growth Rates. See ir.criver.com for reconciliations of Non-GAAP to GAAP results.
10%
$2.9B
11.5%
7.0%
See ir.criver.com for reconciliations of Non-GAAP to GAAP results.
14.8%
20.0%
100 bps increase from fiscal 2019
$7.20
$8.13
20.8% increase from fiscal 2019
64%
25%
Click here to confirm your system meets the minimum requirements(opens in new window)
Should you have any questions or require assistance please contact the Q4 Inc. Investor Day support team investordays@q4inc.com